User login
Medical management of chronic rhinosinusitis with nasal polyposis (CRSwNP) typically has focused on controlling tissue inflammation. Approximately 85% of patients will exhibit a type 2 inflammatory pattern, and recent studies have examined the implications of this process for the treatment of CRSwNP.
As in other respiratory diseases, emerging CRSwNP endotypes are helping researchers identify actionable targets and develop targeted biologic treatments. In fact, therapies targeting cytokines IL-4 and IL-13, which contribute to type 2 inflammation in CRSwNP, recently have been approved by the FDA.
Dr Stella Lee from the University of Pittsburgh discusses the use of new biologic therapies in clinical practice as well as strategies to test for potential drivers of type 2 inflammation.
---
Stella Lee, MD, Chief, Sinonasal Disorder and Allergy; Assistant Professor, Otolaryngology, Department of Head & Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania .
Stella Lee, MD, has disclosed the following relevant financial relationships:
Received research grant from: sanofi-aventis; Regeneron Pharmaceuticals Inc; GlaxoSmithKline; AstraZeneca Pharmaceuticals LP; Genentech.
Medical management of chronic rhinosinusitis with nasal polyposis (CRSwNP) typically has focused on controlling tissue inflammation. Approximately 85% of patients will exhibit a type 2 inflammatory pattern, and recent studies have examined the implications of this process for the treatment of CRSwNP.
As in other respiratory diseases, emerging CRSwNP endotypes are helping researchers identify actionable targets and develop targeted biologic treatments. In fact, therapies targeting cytokines IL-4 and IL-13, which contribute to type 2 inflammation in CRSwNP, recently have been approved by the FDA.
Dr Stella Lee from the University of Pittsburgh discusses the use of new biologic therapies in clinical practice as well as strategies to test for potential drivers of type 2 inflammation.
---
Stella Lee, MD, Chief, Sinonasal Disorder and Allergy; Assistant Professor, Otolaryngology, Department of Head & Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania .
Stella Lee, MD, has disclosed the following relevant financial relationships:
Received research grant from: sanofi-aventis; Regeneron Pharmaceuticals Inc; GlaxoSmithKline; AstraZeneca Pharmaceuticals LP; Genentech.
Medical management of chronic rhinosinusitis with nasal polyposis (CRSwNP) typically has focused on controlling tissue inflammation. Approximately 85% of patients will exhibit a type 2 inflammatory pattern, and recent studies have examined the implications of this process for the treatment of CRSwNP.
As in other respiratory diseases, emerging CRSwNP endotypes are helping researchers identify actionable targets and develop targeted biologic treatments. In fact, therapies targeting cytokines IL-4 and IL-13, which contribute to type 2 inflammation in CRSwNP, recently have been approved by the FDA.
Dr Stella Lee from the University of Pittsburgh discusses the use of new biologic therapies in clinical practice as well as strategies to test for potential drivers of type 2 inflammation.
---
Stella Lee, MD, Chief, Sinonasal Disorder and Allergy; Assistant Professor, Otolaryngology, Department of Head & Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania .
Stella Lee, MD, has disclosed the following relevant financial relationships:
Received research grant from: sanofi-aventis; Regeneron Pharmaceuticals Inc; GlaxoSmithKline; AstraZeneca Pharmaceuticals LP; Genentech.
